CHBRP

Senate Bill 427 (2023) Analysis at a Glance

Antiretroviral Drugs, Devices, and Products as amended on 3/21/2023

Background Context



There is no cure for HIV/AIDS. However, through the use of ARVs — known for inhibiting viral replication and allowing for immune reconstitution — HIVrelated morbidity and mortality can be prevented.



A primary goal of ARVs is to reduce the risk of HIV transmission to sexual partners and to infants born to persons with HIV. ARVs are widely accepted as effective treatment for the control of HIV as well as the prevention of transmission of HIV.

Insurance Subject to the Mandate



CDI and DMHC Regulated (Commercial & CalPERS)



Medi-Cal (but no impact due to pharmacy benefit carve out)

Medical Effectiveness



• Inconclusive evidence on the effect of

Bill Summary



The version of California Senate Bill (SB) 427 analyzed by CHBRP would require DMHC-regulated health plans and CDI-regulated health to cover all U.S. Food and Drug Administration (FDA)approved or Centers for Disease Control and Prevention (CDC)recommended antiretroviral drugs, products, and devices (ARVs) for HIV/AIDS with no cost sharing or utilization review requirements for enrollees in grandfathered and nongrandfathered plans and policies under the outpatient prescription drug benefit.






Federally Regulated (Medicare, self-insured products, etc.)

Medi-Cal COHS

- cost sharing for ARVs on long-term adherence and viral suppression for people living with HIV.
- Insufficient evidence on the effects of cost sharing and utilization management for ARVs on healthcare utilization and health outcomes.

Benefit Coverage and Cost Impacts

At baseline, 98.9% of enrollees with DMHC- or CDI-regulated health insurance plans/policies have coverage for ARVs, and 38.6% of enrollees have coverage for ARV that is fully compliant with SB 427. Postmandate, 100% of enrollees with coverage subject to SB 427 would have coverage for ARV without cost sharing or utilization review requirements.







SB 427 would increase total net annual expenditures by \$51,601,000 or 0.0352% for enrollees with state-regulated insurance, excluding DMHC-regulated Medi-Cal

Public Health Impacts



CHBRP estimates an additional 1,402 enrollees would seek ARVs overall for the prevention or treatment for HIV/AIDS. Including an increase in the number of individuals who do not seroconvert due to PrEP (47) and PEP (22) access, an increase in the number of HIVpositive individuals who access ARV and sustain linkages to care (1,332), and a subsequent decrease in both short- and longterm adverse health outcomes.

Acquired Immunodeficiency Syndrome (AIDS), Antiretroviral drugs, devices, and products (ARVs), California Health Benefits Review Program (CHBRP), California Department of Managed Health Care (DMHC), CA Department of Insurance (CDI), County Organized Health System (COHS), Human Immunodeficiency Virus (HIV)

www.chbrp.org